
Hoth Therapeutics (HOTH) Stock Forecast & Price Target
Hoth Therapeutics (HOTH) Analyst Ratings
Bulls say
Hoth Therapeutics Inc is advancing its clinical pipeline with a disciplined approach to expense management, demonstrating a strategic commitment to develop therapies for unmet medical needs, including oncology and neuroinflammatory diseases. The positive impact of their joint venture programs and progress in IND-enabling work is anticipated to create incremental value, further solidifying Hoth's dual-track strategy. Additionally, promising clinical trial results indicate that over 65% of participants experienced reductions in pain and pruritus, suggesting strong potential for therapeutic efficacy and overall symptom improvement.
Bears say
Hoth Therapeutics Inc reported a significant net loss of approximately $4.11 million for the quarter, translating to a loss of $(0.30) per share, which highlights ongoing financial challenges. The company recorded no revenues during the quarter, continuing a trend that underscores the absence of product commercialization or market entry. Additionally, although total operating expenses decreased from $3.4 million to $2.2 million compared to the previous quarter, the persistent lack of revenue raises concerns about the financial sustainability of Hoth Therapeutics's operations and future growth potential.
This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Hoth Therapeutics (HOTH) Analyst Forecast & Price Prediction
Start investing in Hoth Therapeutics (HOTH)
Order type
Buy in
Order amount
Est. shares
0 shares